Phase I Study Investigates Combination of Ruxolitinib plus Abemaciclib in Myelofibrosis
By Leah Sherwood, Jan Bewersdorf, MD - Last Updated: February 8, 2024Jan Bewersdorf, MD, Chief Fellow at Memorial Sloan Kettering Cancer Center, discusses the challenges and unmet needs in myelofibrosis, and his current ongoing phase I study investigating the combination of ruxolitinib and abemaciclib.
Advertisement
Dr. Bewersdorf presented his poster titled, “A phase I study of ruxolitinib in combination with abemaciclib for patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis,” during the 2023 American Association for Cancer Research Annual Meeting in Orlando, Florida.
Post Tags:AACR 2023
Advertisement
Related Posts
Investigators observed that overall treatment has improved but hospitalizations and other events indicate unaddressed need.
Harboring high molecular risk mutations and a lower JAK2V617F VAF were independent adverse prognostic factors for survival.
The Myelofibrosis Symptom Assessment Form is the only instrument currently available for evaluating myelofibrosis symptoms.
According to John O. Mascarenhas, MD, the phase 3 MANIFEST study heralds a new era of combination therapy for myelofibrosis.
In a phase 2 trial the hepcidin mimetic increased hematocrit control while reducing phlebotomy and patient-reported symptoms.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.